PRO-CTCAETM: PATIENT-REPORTED OUTCOMES VERSION OF CTCAE

Lori Minasian, MD

Deputy Director, Division of Cancer Prevention, NCI

Disclosures

- I work for the USA Federal Government
- I have no financial conflicts to disclose
- Presenting on behalf of the NCI PRO-CTCAE Scientific Leadership Team

Outline of Talk

- Psychometric development for PRO-CTCAE[™]
- Describe initial principles for use
- Identify differences
 - between HRQOL tools and toxicity reporting

What is PRO-CTCAE™?

- PRO-CTCAE is designed for patient reporting of symptomatic adverse events
- PRO-CTCAE is an item bank of questions
 - Derived from the CTCAE adverse event items
 - Complimentary to CTCAE (and to be used with)
- PRO-CTCAE is ONLY for descriptive reporting
 - Not ready for clinical and protocol specific decisionmaking based upon individual PRO-CTCAE scores

PRO-CTCAE Measurement System

1. Symptom Library

- 78 symptomatic adverse events drawn from CTCAE
- PRO-CTCAE questions evaluate symptom occurrence, frequency, severity, and interference


2. System for Survey Administration

- Web-based system to customize surveys and manage survey administration
- Patient responds to surveys using web, tablet or interactive voice response (IVRS) telephone system
- Conditional branching (skip patterns)
- Write-ins with automatic mapping to standardized terminology

For more information, visit: http://outcomes.cancer.gov/tools/pro-ctcae.html



- Psychometrically robust library of items
- Electronic system fits data collection smoothly into trials workflow and offers favorable user-experience
- Accommodate patients with limited English proficiency/digital literacy
- Supply meaningful data to improve understanding of symptomatic AEs



Funded by NCI contracts HHSN261200800043C, HHSN261201000063C, and

PRO-CTCAE Content Validity

- 78 symptomatic AEs identified from ~800 CTCAE terms for patient self-reporting
 - Plain-language AE terms identified
- Each symptomatic AE has 1 to 3 items¹
 - Frequency, severity, interference w/ activities
- Content validity established during three interview rounds with semi-structured interview using structured and open-ended probes (N=127)²
 - 63/80 symptom terms generated no cognitive difficulties; 17 modified and re-tested without further difficulties

¹Basch et al., (2014). Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Journal of the National Cancer Institute*, 106(9). pii: dju244

²Hay et al. (2014). Cognitive interviewing of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to support content validity. *Quality of Life Research*, 23(1):257-269

PATIENT-REPORTED OUTCOMES VERSION OF THE COMMON TERMINOLOGY **CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE™) ITEM LIBRARY (Version 1.0)**

SI

SI

SI

SI

FSI

FSI

FSI

FSI

\cap	ra	
U J	а	

S
S
SI
S
Ρ
S
al
S
SI
FS
FS
FS
Ρ
FS
FS
S
F
FSI
FI

Respiratory	
Shortness of breath	SI
Cough	SI
Wheezing	S

Cardio/Circulat	ory
Swelling	FSI
Heart palpitations	FS
Cutaneous	
Rash	Р
Skin dryness	S
Acne	S
Hair loss	Р
Itching	S
Hives	Ρ
Hand-foot syndrome	S
Nail loss	Р
Nail ridging	Р
Nail discoloration	Ρ
Sensitivity to sunlight	Ρ
Bed/pressure sores	Р
Radiation skin reaction	S
Skin darkening	Ρ
Stretch marks	Ρ

Neurologica	al
Numbness & tingling	; SI
Dizziness	SI
Visual/Percep	tual
Blurred vision	SI
Flashing lights	Р
Visual floaters	Р
Watery eyes	SI
Ringing in ears	S
Attention/Mer	nory
Concentration	SI
Memory	SI
Pain	
General pain	FSI
Headache	FSI
Muscle pain	FSI
Joint pain	FSI

Sleep/Wake		Sexual
Insomnia	SI	Achieve and
Fatigue	SI	maintain erection
		Ejaculation
Mood		Decreased libido
Anxious	FSI	Delayed orgasm
Discouraged	FSI	Unable to have
Sad	FSI	orgasm
		Pain w/sexual intercourse
		intercourse
Gynecologic/Uri	nary	Miscellaneous
Irregular		Breast swelling and
periods/vaginal	Р	tenderness
bleeding		Bruising
Missed expected menstrual period	Р	Chills
Vaginal discharge	Р	Increased sweating
Vaginal dryness	S	Decreased sweating
Painful urination	S	Hot flashes
Urinary urgency	FI	Nosebleed
Urinary frequency	PI	Pain and swelling at
		injection site
Change in usual urine color	Ρ	Body odor
Urinary incontinence	FI	

S

F

S

Ρ

Ρ

S

S

Ρ

FS

FS

Ρ

FS

FS

Ρ

S

NAL	INST
OLA	
Z	
HE	ALT



Dimensions		
F: Frequency	I: Interference	
S: Severity	P: Presence/Absence /Amount	


PRO-CTCAE Validity and Reliability

- Results demonstrate favorable validity, reliability, and responsiveness of PRO-CTCAE in a large, heterogeneous sample of patients undergoing cancer treatment (n=940)¹
 - Most PRO-CTCAE items (119/124) reached a statistically significant (p<0.05) and meaningful effect size on one or more validity criteria
 - Majority of the items tested (n=27 items) exhibited acceptable testretest reliability
 - All tested items (n=27 items) were sensitive to differences between groups

Validity and reliability of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncology, Epub ahead of print.

Comparison of Recall Periods

- N=110 patients completed 27 PRO-CTCAE items (14 symptomatic A/Es)
 - Comparison of 28 daily ratings to 1-, 2-, 3-, and 4-week recalled ratings
 - 1-week recall corresponds well to daily reporting. Differences between daily and longer recall periods widen with 2, 3, and 4 week recall



Mendoza et al. Evaluation of different recall periods for the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Manuscript in preparation for *Clinical Trials*.

Timeframe for Assessments

- Recall period is 7 days
 - Anticipate weekly reporting
 - Currently, data to demonstrate ~ 90% compliance for weekly reporting up to 20 weeks with reminders.
 - Baseline and off-study assessment are essential
 - Balance number of items asked and frequency of time for assessments with data quality
- If asking questions with an interval of longer than one week, the recall period remains the last 7 days

Mode Equivalence

- N=112 patients completed 28 PRO-CTCAE items (14 symptomatic AEs) by each of the three modes of administration at a single clinic visit
- Average time to complete an item:
 - Web: 11.1 seconds (SD = ± 8.4)
 - Interactive Voice Response (IVRS): 16.3 seconds (SD = \pm 6.3)
 - Paper: 10.3 seconds (SD = ± 5.8)

Between modes, item-level mean differences were very small, and the corresponding effect sizes were all less than 0.20

	Median ICC (Range)	Median (range) between-mode item- level mean difference
Web vs IVRS	0.78 (0.56 - 0.90)	-0.04 (-0.16 - 0.22)
Web vs paper	0.81 (0.61 - 0.96)	-0.02 (-0.11 - 0.14)
IVRS vs paper	0.78 (0.59 - 0.91)	0.02 (-0.07 - 0.19)

Bennett et al. (2016). Health and Quality of Life Outcomes. E Pub ahead of print.

Technology May Improve Data Collection


- Electronic administration reduces the number of items that must be asked of patients
 - Conditional branching
 - Computer adaptive testing
- Technology has enabled data collection to be more efficient, customized, mobile, and responsive
 - Smart phone/hand-held devices/Interactive Voice Response (IVRS) for data collection
 - Customize time of day for assessment, text size on screen, and mode of administration
 - Reminders to patients and staff for missed surveys
 - Eliminate need for data entry
 - Mobile devices may improve engagement







Example from Actual Trial: Compliance over Time Weekly reporting from home via Web or IVRS (patient choice), with central monitoring and backup human telephone calls



Supported by NCI contract HHSN261201000063C



NATIONAL CANCER INSTITUTE Division of Cancer Control & Population Sciences 🖨 Print Page 👘 🔽 E-mail Page

Q

Search HDRP

Healthcare Delivery Research Program **Data Resources and Research Initiatives Funding Opportunities** Home **Research Portfolio** About -Blog Data Resources and Research Initiatives Measurement of Outcomes Measurement of Outcomes Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) CanCORS Patient-Reported Outcomes version of the Common HealthMeasures: A Person-Centered Assessment Resource (PCAR) Terminology Criteria for Adverse Events (PRO-CTCAE[™]) **Patient-Reported Outcomes Version**

This site was designed to provide you with information about the PRO-CTCAE, a patient-reported outcome measurement system developed by the National Cancer Institute to capture symptomatic adverse events in patients on cancer clinical trials.

The site includes an overview of the methods used to develop this measurement system, and resources and references for further information.

- ▶ What Is PRO-CTCAE?
- ▶ How Do I Use PRO-CTCAE?
- Overview
- Instrument
- Permission to Use
- ▶ Build a Custom Form
 - Development Team
 - PRO-CTCAE Scientific Leadership at NCI
 - Resources
 - ► Frequently Asked Questions

Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)

What Is PRO-CTCAE?

How Do I Use PRO-CTCAE?

Overview

Instrument

Permission to Use

Build a Custom Form

Development Team

PRO-CTCAE Scientific Leadership at NCI

Resources

Frequently Asked Questions

Toxicity Reporting & PRO-CTCAE

Toxicity Reporting

- Clinician assesses adverse events and grade events
- Action is taken based upon protocol specific instructions for the purpose of preventing or reducing harm
- Events reviewed in real time and study design may be modified
- Each event is reported and analyzed independently

PRO-CTCAE

- Patient answers separate questions about occurrence of event
- If event occurs, answer questions about frequency, severity or interference
- No protocol directed modifications based only on patient reports
- Each event evaluated individually (No summary score)

CTCAE Use Within Clinical Trials

- Protocol parameters
 - Patient Eligibility
 - Dose Limiting Toxicity (DLT)
 - Maximum Tolerated Dose (MTD) determination
 - Dose Modification
- Recommended Phase 2 dose
- Reporting of both routine adverse events and serious adverse events (SAE)
- Monitor safety data and regulatory reporting

CTCAE vs. PRO-CTCAE[™] Item Structures

CTCAE					
Adverse	erse Grade				
Event	1	2	3	4	5
Mucositis oral	Asymptomatic or mild symptoms; intervention not indicated	Moderate pain; not interfering with oral intake; modified diet indicated	Severe pain; interfering with oral intake	Life-threatening consequences; urgent intervention indicated	-
	PRO-CTCAE				
Please think	Please think back over <u>the past 7 days:</u>				
What was the <u>severity</u> of your MOUTH OR THROAT SORES at their WORST? None / Mild / Moderate / Severe / Very severe					
How much did MOUTH OR THROAT SORES <u>interfere</u> with your usual or daily activities? Not at all / A little bit / Somewhat / Quite a bit / Very much					

PRO-CTCAE Score vs. CTCAE Grade

PRO-CTCAE responses are scored from 0 to 4

- Up to three questions per AE Item
 - Frequency, Severity, Interference
- Clinician CTCAE Grade
 - Bundles the constructs of severity, frequency and interference
 - Grading dependent upon clinician judgement of medical significance
- Clinician Grade ≠ PRO-CTCAE Score
 - One grade by clinician
 - Up to three patient reported scores per Item
 - CTCAE Grade 4 does not exist for most of the PRO-CTCAE items

HRQOL *[≠]* Toxicity Reporting

- HRQOL
 - Questions designed to address overall effects of cancer and its treatment
 - Patient answers questions in real time
 - Responses evaluated by study at the completion of the study
 - Tools are designed to provide a summary score
- Toxicity Reporting
 - Clinician assesses adverse events for patient safety
 - Action is taken specifically to reducing further harm
 - Events reviewed in real time and study design may be modified
 - Each event is reported independently

Key Points

- Different tools used for different purposes
- HRQOL provides an assessment for multiple different domains on how a patient experiences the combination of cancer, its treatment and related effects.

 Toxicity reporting is specific to safety and patients may not be aware of what is treatment related or cancer related.

Key Points

- PRO-CTCAE is a new tool:
- Derived from clinician rated CTCAE for the purpose of refining the understanding of adverse events as a consequence of treatment.
- Clinician graded CTCAE remains standard for protocol directed action specific individual adverse events
- PRO-CTCAE provides descriptive information to compliment clinician reporting
- Much more work is needed to understand how best to use PRO-CTCAE data.

Ongoing Work

- Responsiveness, minimal clinically important difference, cut-points, relationship among the attributes
- Several languages in development/validation, including Chinese, Korean, Italian, French, Swedish, Dutch, and Danish
- Evaluate different approaches to patient-investigator grade reconciliation and to analyzing and representing PRO-CTCAE data



NCI PRO-CTCAE Study Group

Supported through NCI contracts HHSN261200800043C and HHSN261201000063C

Ethan Basch Sandra Mitchell

Amy Abernethy Jeff Abrams Suneel Allareddy **Benjamin Arnold Pamela Atherton Thomas Atkinson** Natalie Barragan **Paul Baumgartner** Lauren Becker Antonia Bennett Nancy Breen **Deborah Bruner** Laurie Burke Kate Castro David Cella Alice Chen Ram Chilukuri Steven Clauser **Charles Cleeland**

Catherine Coleman **Stephanie Consoli Cori Couture** Andrea Denicoff **Amylou Dueck** Jana Eisenstein Maria Fawzy Shanda Finnigan **Steve Friedman** Joshua Gagne Vinay Gangoli Marcha Gatewood Araceli Garcia-Gonzalez **Cindy Geoghegan** Maria Gonzalez Mehul Gulati **Gaurav Gupta** Jennifer Hay Madeline Hernandez-Krause Jessica Hess Lori Hudson Norval Johnson

Joseph Kelaghan **Reshma Koganti** Edward Korn **George Komatsoulis** Virginia Kwitkowski Suzanne Lechner Lauren Lent Yuelin Li **Carol Lowenstein** Donna Malveaux **Michael Mejia** Tito Mendoza Lori Minasian Michael Montello Hannah O'Gorman Ann O'Mara Diane Paul John Payne Frank Penedo Barbara Perez **Richard Piekarz** Liora Pollick

Katherine Ramsey Bryce Reeve Lauren Rogak **Dave Rothfarb** Sean Ryan Daniel Satele Martin Schoen **Deborah Schrag** Ann Setser **Eve Shalley Mary Shaw** Marwan Shouery Laura Sit Jeff Sloan Diane St. Germain Ann Marie Trentascosti Ted Trimble Andy Trotti **Andrea Vinard** Vish Viswanath Gordon Willis Jennifer Wind

NCI Community Cancer Centers Program (NCCCP), RTOG, Alliance, FDA We gratefully acknowledge our study participants and patient representatives!